HRP20100272T2 - Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4) - Google Patents

Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4) Download PDF

Info

Publication number: HRP20100272T2
Authority: HR; Croatia
Prior art keywords: cr12ar12b; alkyl; hydrogen; amino; sulfonyl
Prior art date: 2005-09-23

Application number

HR20100272T

Other languages

English (en)

Croatian (hr)

Inventor

Douglas Patterson Brian

Kim Sakata Sylvie

D. Nambu Mitchell

Bharat Kumar Patel Leena

Howard Tatlock John

Original Assignee

Pfizer Products Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-23

Filing date

2010-05-14

Publication date

2010-07-31

2010-05-14 Application filed by Pfizer Products Incorporated filed Critical Pfizer Products Incorporated

2010-06-30 Publication of HRP20100272T1 publication Critical patent/HRP20100272T1/xx

2010-07-31 Publication of HRP20100272T2 publication Critical patent/HRP20100272T2/hr

Links

102000004328 Cytochrome P-450 CYP3A Human genes 0.000 title 2
108010081668 Cytochrome P-450 CYP3A Proteins 0.000 title 2
229940054066 benzamide antipsychotics Drugs 0.000 title 1
150000003936 benzamides Chemical class 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract 27
229910052739 hydrogen Inorganic materials 0.000 claims abstract 27
239000001257 hydrogen Substances 0.000 claims abstract 27
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 16
125000003118 aryl group Chemical group 0.000 claims abstract 13
125000006694 (C2-C10) heterocyclyl group Chemical group 0.000 claims abstract 12
150000003839 salts Chemical class 0.000 claims abstract 12
239000012453 solvate Substances 0.000 claims abstract 12
125000000753 cycloalkyl group Chemical group 0.000 claims abstract 11
125000001072 heteroaryl group Chemical group 0.000 claims abstract 11
125000000041 C6-C10 aryl group Chemical group 0.000 claims abstract 10
125000000623 heterocyclic group Chemical group 0.000 claims abstract 8
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 6
229910052736 halogen Inorganic materials 0.000 claims abstract 5
150000002367 halogens Chemical class 0.000 claims abstract 4
125000004429 atom Chemical group 0.000 claims abstract 3
-1 C 1 -C 6 alkyl Inorganic materials 0.000 claims 15
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
150000002431 hydrogen Chemical group 0.000 claims 8
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims 6
108010019625 Atazanavir Sulfate Proteins 0.000 claims 5
KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 5
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims 5
AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 claims 5
HINZVVDZPLARRP-YSVIXOAZSA-N (4r,5s,6s,7r)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.NC1=CC=CC(CN2C(N(CC=3C=C(N)C=CC=3)[C@H](CC=3C=CC=CC=3)[C@H](O)[C@@H](O)[C@H]2CC=2C=CC=CC=2)=O)=C1 HINZVVDZPLARRP-YSVIXOAZSA-N 0.000 claims 4
BEUUJDAEPJZWHM-COROXYKFSA-N tert-butyl n-[(2s,3s,5r)-3-hydroxy-6-[[(2s)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate Chemical compound C([C@@H]([C@@H](O)C[C@H](C(=O)N[C@H](C(=O)NCCOC)C(C)C)CC=1C(=C(OC)C(OC)=CC=1)OC)NC(=O)OC(C)(C)C)C1=CC=CC=C1 BEUUJDAEPJZWHM-COROXYKFSA-N 0.000 claims 4
AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims 3
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims 3
241000124008 Mammalia Species 0.000 claims 3
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 3
SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 claims 3
229960001830 amprenavir Drugs 0.000 claims 3
230000036436 anti-hiv Effects 0.000 claims 3
229960003277 atazanavir Drugs 0.000 claims 3
229950009079 brecanavir Drugs 0.000 claims 3
JORVRJNILJXMMG-OLNQLETPSA-N brecanavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=C2OCOC2=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C(C=C1)=CC=C1OCC1=CSC(C)=N1 JORVRJNILJXMMG-OLNQLETPSA-N 0.000 claims 3
PMDQGYMGQKTCSX-HQROKSDRSA-L calcium;[(2r,3s)-1-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-[[(3s)-oxolan-3-yl]oxycarbonylamino]-4-phenylbutan-2-yl] phosphate Chemical compound [Ca+2].C([C@@H]([C@H](OP([O-])([O-])=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 PMDQGYMGQKTCSX-HQROKSDRSA-L 0.000 claims 3
229960005107 darunavir Drugs 0.000 claims 3
CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims 3
229960002933 fosamprenavir calcium Drugs 0.000 claims 3
229960001936 indinavir Drugs 0.000 claims 3
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims 3
229940088976 invirase Drugs 0.000 claims 3
229960004525 lopinavir Drugs 0.000 claims 3
229960000884 nelfinavir Drugs 0.000 claims 3
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims 3
229950006460 palinavir Drugs 0.000 claims 3
RXBWRFDZXRAEJT-SZNOJMITSA-N palinavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)[C@H](O)CN1[C@@H](C[C@@H](CC1)OCC=1C=CN=CC=1)C(=O)NC(C)(C)C)C1=CC=CC=C1 RXBWRFDZXRAEJT-SZNOJMITSA-N 0.000 claims 3
229960000311 ritonavir Drugs 0.000 claims 3
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 3
229960001852 saquinavir Drugs 0.000 claims 3
229960000838 tipranavir Drugs 0.000 claims 3
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
IXZYCIFRVZKVRJ-RKKDRKJOSA-N (2s)-n-[(2s,3r)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-[[2-[(3-fluorophenyl)methylamino]acetyl]amino]-3,3-dimethylbutanamide Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)[C@@H](NC(=O)CNCC=1C=C(F)C=CC=1)C(C)(C)C)C1=CC=CC=C1 IXZYCIFRVZKVRJ-RKKDRKJOSA-N 0.000 claims 2
CUFQBQOBLVLKRF-RZDMPUFOSA-N (4r)-3-[(2s,3s)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-5,5-dimethyl-n-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide Chemical compound CC1=CC=CC=C1CNC(=O)[C@@H]1C(C)(C)SCN1C(=O)[C@@H](O)[C@@H](NC(=O)C=1C(=C(O)C=CC=1)C)CC1=CC=CC=C1 CUFQBQOBLVLKRF-RZDMPUFOSA-N 0.000 claims 2
208000031886 HIV Infections Diseases 0.000 claims 2
208000037357 HIV infectious disease Diseases 0.000 claims 2
NJBBLOIWMSYVCQ-VZTVMPNDSA-N Kynostatin 272 Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)COC=1C2=CC=NC=C2C=CC=1)CSC)[C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)C1=CC=CC=C1 NJBBLOIWMSYVCQ-VZTVMPNDSA-N 0.000 claims 2
125000004093 cyano group Chemical group *C#N 0.000 claims 2
239000003814 drug Substances 0.000 claims 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
108010075606 kynostatin 272 Proteins 0.000 claims 2
NYGRNTSORGSTJK-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[(4-ethoxypyridin-3-yl)sulfamoyl]-n-methylbenzamide Chemical compound CCOC1=CC=NC=C1NS(=O)(=O)C1=CC=CC=C1C(=O)N(C)CC1=CC=C(F)C(F)=C1 NYGRNTSORGSTJK-UHFFFAOYSA-N 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
ZOCLBCDMJXZMHF-UHFFFAOYSA-N 2-[(4-ethoxypyridin-3-yl)sulfamoyl]-n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound CCOC1=CC=NC=C1NS(=O)(=O)C1=CC=CC=C1C(=O)NCC1=CC=C(F)C(C(F)(F)F)=C1 ZOCLBCDMJXZMHF-UHFFFAOYSA-N 0.000 claims 1
HCKHZGMYCRMGNN-UHFFFAOYSA-N 2-[(5-ethoxypyridin-3-yl)sulfamoyl]-n-[2-(2-methylphenyl)ethyl]benzamide Chemical compound CCOC1=CN=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(=O)NCCC=2C(=CC=CC=2)C)=C1 HCKHZGMYCRMGNN-UHFFFAOYSA-N 0.000 claims 1
CNXACKFWYRYUCW-UHFFFAOYSA-N 2-[(5-ethoxypyridin-3-yl)sulfamoyl]-n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound CCOC1=CN=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(=O)NCC=2C=C(C(F)=CC=2)C(F)(F)F)=C1 CNXACKFWYRYUCW-UHFFFAOYSA-N 0.000 claims 1
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
229940122440 HIV protease inhibitor Drugs 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
239000004030 hiv protease inhibitor Substances 0.000 claims 1
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
RIEHXZKHLIMPRG-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]-2-[(5-ethoxypyridin-3-yl)sulfamoyl]benzamide Chemical compound CCOC1=CN=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(=O)NCC=2C=C(Cl)C(Cl)=CC=2)=C1 RIEHXZKHLIMPRG-UHFFFAOYSA-N 0.000 claims 1
ZWRFIJHLXJKXTN-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]-2-[(5-methylpyridin-3-yl)sulfamoyl]benzamide Chemical compound CC1=CN=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(=O)NCC=2C=C(Cl)C(Cl)=CC=2)=C1 ZWRFIJHLXJKXTN-UHFFFAOYSA-N 0.000 claims 1
WZPOEIYGBPZWFU-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[(4-ethoxypyridin-3-yl)sulfamoyl]benzamide Chemical compound CCOC1=CC=NC=C1NS(=O)(=O)C1=CC=CC=C1C(=O)NCC1=CC=C(F)C(F)=C1 WZPOEIYGBPZWFU-UHFFFAOYSA-N 0.000 claims 1
KVPBBXNZIREVEW-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[(4-methoxypyridin-3-yl)sulfamoyl]-n-methylbenzamide Chemical compound COC1=CC=NC=C1NS(=O)(=O)C1=CC=CC=C1C(=O)N(C)CC1=CC=C(F)C(F)=C1 KVPBBXNZIREVEW-UHFFFAOYSA-N 0.000 claims 1
AIXZEHAFOAWCBI-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[(4-methoxypyridin-3-yl)sulfamoyl]benzamide Chemical compound COC1=CC=NC=C1NS(=O)(=O)C1=CC=CC=C1C(=O)NCC1=CC=C(F)C(F)=C1 AIXZEHAFOAWCBI-UHFFFAOYSA-N 0.000 claims 1
BKNCIMAPPAXVNR-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[(5-methoxypyridin-3-yl)sulfamoyl]benzamide Chemical compound COC1=CN=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(=O)NCC=2C=C(F)C(F)=CC=2)=C1 BKNCIMAPPAXVNR-UHFFFAOYSA-N 0.000 claims 1
QVOWRNNWQKOAJN-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-2-[(5-methylpyridin-3-yl)sulfamoyl]benzamide Chemical compound CC1=CN=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(=O)NCC=2C=C(Cl)C=C(Cl)C=2)=C1 QVOWRNNWQKOAJN-UHFFFAOYSA-N 0.000 claims 1
VKLFHKFXCIIWSR-UHFFFAOYSA-N n-[(3-chloro-2-methylphenyl)methyl]-2-[(5-methoxypyridin-3-yl)sulfamoyl]benzamide Chemical compound COC1=CN=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(=O)NCC=2C(=C(Cl)C=CC=2)C)=C1 VKLFHKFXCIIWSR-UHFFFAOYSA-N 0.000 claims 1
TXMAHYZRZXTSDE-UHFFFAOYSA-N n-[(4-chloro-2-methylphenyl)methyl]-2-[(5-methoxypyridin-3-yl)sulfamoyl]benzamide Chemical compound COC1=CN=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(=O)NCC=2C(=CC(Cl)=CC=2)C)=C1 TXMAHYZRZXTSDE-UHFFFAOYSA-N 0.000 claims 1
UCEXMYNDLQJYOM-UHFFFAOYSA-N n-[2-(2-fluorophenyl)ethyl]-2-[(5-methoxypyridin-3-yl)sulfamoyl]benzamide Chemical compound COC1=CN=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(=O)NCCC=2C(=CC=CC=2)F)=C1 UCEXMYNDLQJYOM-UHFFFAOYSA-N 0.000 claims 1
LFXBOBVVGLBSHE-UHFFFAOYSA-N n-[2-(2-methylphenyl)ethyl]-2-[(5-methylpyridin-3-yl)sulfamoyl]benzamide Chemical compound CC1=CN=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(=O)NCCC=2C(=CC=CC=2)C)=C1 LFXBOBVVGLBSHE-UHFFFAOYSA-N 0.000 claims 1
CYFWKTRCWDFGNM-UHFFFAOYSA-N n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-2-[(4-methoxypyridin-3-yl)sulfamoyl]benzamide Chemical compound COC1=CC=NC=C1NS(=O)(=O)C1=CC=CC=C1C(=O)NCC1=CC=C(F)C(C(F)(F)F)=C1 CYFWKTRCWDFGNM-UHFFFAOYSA-N 0.000 claims 1
YFHUJXZHIOMPFO-UHFFFAOYSA-N n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-2-[(5-methoxypyridin-3-yl)sulfamoyl]benzamide Chemical compound COC1=CN=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(=O)NCC=2C=C(C(F)=CC=2)C(F)(F)F)=C1 YFHUJXZHIOMPFO-UHFFFAOYSA-N 0.000 claims 1
NKERIASEZLPHHZ-UHFFFAOYSA-N n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-2-[(5-methylpyridin-3-yl)sulfamoyl]benzamide Chemical compound CC1=CN=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(=O)NCC=2C=C(C(F)=CC=2)C(F)(F)F)=C1 NKERIASEZLPHHZ-UHFFFAOYSA-N 0.000 claims 1
125000001424 substituent group Chemical group 0.000 claims 1
102220475869 Keratin, type I cytoskeletal 10_R12A_mutation Human genes 0.000 abstract 2
101000596772 Homo sapiens Transcription factor 7-like 1 Proteins 0.000 abstract 1
101000666382 Homo sapiens Transcription factor E2-alpha Proteins 0.000 abstract 1
102100035097 Transcription factor 7-like 1 Human genes 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

HR20100272T 2005-09-23 2010-05-14 Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4) HRP20100272T2 (hr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US72015105P	2005-09-23	2005-09-23
US72311505P	2005-10-03	2005-10-03
US72546905P	2005-10-11	2005-10-11
US76225606P	2006-01-25	2006-01-25
US82166406P	2006-08-07	2006-08-07
PCT/IB2006/002639 WO2007034312A2 (fr)	2005-09-23	2006-09-11	Composes therapeutiques

Publications (2)

Publication Number	Publication Date
HRP20100272T1 HRP20100272T1 (en)	2010-06-30
HRP20100272T2 true HRP20100272T2 (hr)	2010-07-31

Family

ID=37889174

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20100272T HRP20100272T2 (hr)	2005-09-23	2010-05-14	Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4)

Country Status (29)

Country	Link
US (1)	US7868026B2 (fr)
EP (1)	EP1937639B1 (fr)
JP (1)	JP4336738B2 (fr)
KR (1)	KR100975448B1 (fr)
CN (1)	CN101287708B (fr)
AT (1)	ATE459603T1 (fr)
AU (1)	AU2006293605B2 (fr)
BR (1)	BRPI0616156A2 (fr)
CA (1)	CA2621805C (fr)
CY (1)	CY1110010T1 (fr)
DE (1)	DE602006012713D1 (fr)
DK (1)	DK1937639T3 (fr)
EA (1)	EA014329B1 (fr)
EC (1)	ECSP088296A (fr)
ES (1)	ES2340200T3 (fr)
GE (1)	GEP20115230B (fr)
HK (1)	HK1120506A1 (fr)
HR (1)	HRP20100272T2 (fr)
IL (1)	IL189666A (fr)
MA (1)	MA29791B1 (fr)
MY (1)	MY143391A (fr)
NO (1)	NO20081844L (fr)
NZ (1)	NZ566136A (fr)
PL (1)	PL1937639T3 (fr)
PT (1)	PT1937639E (fr)
RS (2)	RS20080118A (fr)
SI (1)	SI1937639T1 (fr)
TN (1)	TNSN08139A1 (fr)
WO (1)	WO2007034312A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ574207A (en) *	2006-07-05	2010-10-29	Pfizer Prod Inc	Pyrazole derivatives as cytochrome p450 inhibitors
AU2007343726A1 (en) *	2006-12-26	2008-07-24	Amgen Inc.	N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
CN101669030B (zh)	2007-03-08	2016-01-13	小利兰·斯坦福大学托管委员会	线粒体醛脱氢酶2调节剂和其使用方法
WO2009043784A1 (fr) *	2007-10-04	2009-04-09	F. Hoffmann-La Roche Ag	Dérivés de cyclopropyl aryl amides et leurs utilisations
JP2012502048A (ja)	2008-09-08	2012-01-26	ボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティ	アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
US8389522B2 (en) *	2008-10-28	2013-03-05	The Board Of Trustees Of The Leland Stanford Junior University	Modulators of aldehyde dehydrogenase and methods of use thereof
DK2385938T3 (en)	2009-01-12	2015-04-27	Pfizer Ltd	Sulfonamidderivater
MX2011011428A (es) *	2009-05-01	2011-11-29	Raqualia Pharma Inc	Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
US9145407B2 (en)	2010-07-09	2015-09-29	Pfizer Limited	Sulfonamide compounds
US10457659B2 (en)	2011-04-29	2019-10-29	The Board Of Trustees Of The Leland Stanford Junior University	Compositions and methods for increasing proliferation of adult salivary stem cells
CN104540813A (zh) *	2012-06-27	2015-04-22	默沙东公司	磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
WO2014000178A1 (fr) *	2012-06-27	2014-01-03	Merck Sharp & Dohme Corp.	Dérivés de sulfamide et leurs méthodes d'utilisation permettant d'améliorer la pharmacocinétique d'un médicament
JP6410790B2 (ja)	2013-03-14	2018-10-24	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
TW201512171A (zh)	2013-04-19	2015-04-01	Pfizer Ltd	化學化合物
WO2014194519A1 (fr)	2013-06-07	2014-12-11	Merck Sharp & Dohme Corp.	Dérivés imidazole et leurs procédés d'utilisation pour l'amélioration des propriétés pharmacocinétiques d'un médicament
WO2015070366A1 (fr)	2013-11-12	2015-05-21	Merck Sharp & Dohme Corp.	Dérivés d'imidazole et de triazole liés à aryle et leurs procédés d'utilisation pour améliorer la pharmacocinétique d'un médicament
WO2015070367A1 (fr) *	2013-11-12	2015-05-21	Merck Sharp & Dohme Corp.	Dérivés d'imidazole et de triazole liés à la pipéridine ou la pipérazine et leurs procédés d'utilisation pour améliorer la pharmacocinétique d'un médicament
HUE046820T2 (hu)	2014-03-26	2020-03-30	Hoffmann La Roche	Biciklusos vegyületek autotaxin (ATX) és lizofoszfatidsav (LPA) termelésgátlókként
WO2016101118A1 (fr) *	2014-12-23	2016-06-30	Merck Sharp & Dohme Corp.	Antagonistes des récepteurs d'orexine de type amidoéthylazole
CR20180058A (es)	2015-09-04	2018-02-26	Hoffmann La Roche	Nuevos derivados de fenoximetilo
WO2018167113A1 (fr)	2017-03-16	2018-09-20	F. Hoffmann-La Roche Ag	Nouveaux composés bicycliques utilisés en tant qu'inhibiteurs d'atx

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7169763B2 (en) *	2002-02-22	2007-01-30	Oliver Yoa-Pu Hu	Cytochrome P450 3A inhibitors and enhancers

2006
- 2006-09-11 WO PCT/IB2006/002639 patent/WO2007034312A2/fr active Application Filing
- 2006-09-11 SI SI200630666T patent/SI1937639T1/sl unknown
- 2006-09-11 DK DK06795544.3T patent/DK1937639T3/da active
- 2006-09-11 PT PT06795544T patent/PT1937639E/pt unknown
- 2006-09-11 KR KR1020087006967A patent/KR100975448B1/ko not_active IP Right Cessation
- 2006-09-11 GE GEAP200610575A patent/GEP20115230B/en unknown
- 2006-09-11 EA EA200800542A patent/EA014329B1/ru not_active IP Right Cessation
- 2006-09-11 AT AT06795544T patent/ATE459603T1/de active
- 2006-09-11 CN CN2006800348278A patent/CN101287708B/zh not_active Expired - Fee Related
- 2006-09-11 EP EP06795544A patent/EP1937639B1/fr active Active
- 2006-09-11 AU AU2006293605A patent/AU2006293605B2/en not_active Ceased
- 2006-09-11 CA CA2621805A patent/CA2621805C/fr not_active Expired - Fee Related
- 2006-09-11 NZ NZ566136A patent/NZ566136A/en not_active IP Right Cessation
- 2006-09-11 RS RSP-2008/0118A patent/RS20080118A/sr unknown
- 2006-09-11 PL PL06795544T patent/PL1937639T3/pl unknown
- 2006-09-11 ES ES06795544T patent/ES2340200T3/es active Active
- 2006-09-11 BR BRPI0616156-1A patent/BRPI0616156A2/pt not_active IP Right Cessation
- 2006-09-11 RS RSP-2010/0237A patent/RS51349B/en unknown
- 2006-09-11 JP JP2008531812A patent/JP4336738B2/ja not_active Expired - Fee Related
- 2006-09-11 DE DE602006012713T patent/DE602006012713D1/de active Active
2007
- 2007-01-09 US US11/621,410 patent/US7868026B2/en not_active Expired - Fee Related
2008
- 2008-02-21 IL IL189666A patent/IL189666A/en not_active IP Right Cessation
- 2008-03-19 MA MA30764A patent/MA29791B1/fr unknown
- 2008-03-19 EC EC2008008296A patent/ECSP088296A/es unknown
- 2008-03-19 TN TNP2008000139A patent/TNSN08139A1/fr unknown
- 2008-03-21 MY MYPI20080779A patent/MY143391A/en unknown
- 2008-04-16 NO NO20081844A patent/NO20081844L/no not_active Application Discontinuation
- 2008-12-15 HK HK08113572.1A patent/HK1120506A1/xx not_active IP Right Cessation
2010
- 2010-04-20 CY CY20101100359T patent/CY1110010T1/el unknown
- 2010-05-14 HR HR20100272T patent/HRP20100272T2/hr unknown

Also Published As

Publication number	Publication date
EP1937639B1 (fr)	2010-03-03
CY1110010T1 (el)	2015-01-14
CA2621805C (fr)	2011-05-10
US20070167497A1 (en)	2007-07-19
EA200800542A1 (ru)	2008-08-29
GEP20115230B (en)	2011-06-10
AU2006293605B2 (en)	2011-05-19
PL1937639T3 (pl)	2010-07-30
ES2340200T3 (es)	2010-05-31
ATE459603T1 (de)	2010-03-15
CN101287708B (zh)	2012-02-29
JP2009508931A (ja)	2009-03-05
RS20080118A (en)	2009-05-06
NZ566136A (en)	2010-04-30
JP4336738B2 (ja)	2009-09-30
MY143391A (en)	2011-05-13
CA2621805A1 (fr)	2007-03-29
HRP20100272T1 (en)	2010-06-30
MA29791B1 (fr)	2008-09-01
IL189666A0 (en)	2008-08-07
DK1937639T3 (da)	2010-05-10
BRPI0616156A2 (pt)	2011-06-07
RS51349B (en)	2011-02-28
ECSP088296A (es)	2008-06-30
CN101287708A (zh)	2008-10-15
NO20081844L (no)	2008-05-29
KR20080038431A (ko)	2008-05-06
TNSN08139A1 (fr)	2009-07-14
WO2007034312A2 (fr)	2007-03-29
DE602006012713D1 (de)	2010-04-15
EA014329B1 (ru)	2010-10-29
US7868026B2 (en)	2011-01-11
WO2007034312A3 (fr)	2007-08-23
KR100975448B1 (ko)	2010-08-11
IL189666A (en)	2011-12-29
AU2006293605A1 (en)	2007-03-29
PT1937639E (pt)	2010-04-23
EP1937639A2 (fr)	2008-07-02
SI1937639T1 (sl)	2010-07-30
HK1120506A1 (en)	2009-04-03

Publication	Publication Date	Title
HRP20100272T2 (hr)	2010-07-31	Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4)
AU2014223973B2 (en)	2016-12-22	Amide compounds for the treatment of HIV
AR084573A1 (es)	2013-05-29	Quinoxalinas y aza-quinoxalinas como moduladores del receptor de crth
HRP20211180T1 (hr)	2021-10-15	Spojevi koji moduliraju androgeni receptor
CA3105748A1 (fr)	2020-01-16	Composes pyridazineg pour inhiber nav1.8
IL264982B (en)	2022-08-01	Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors
DE602004021959D1 (de)	2009-08-20	Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor
PH12019500659A1 (en)	2019-12-16	Pyrazolopyridine derivative having glp-1 receptor agonist effect
CA2672373A1 (fr)	2008-06-26	Derives de la nicotinamide en tant qu'inhibiteurs de h-pgds et leur utilisation dans le traitement de maladies liees aux prostaglandines d2
HRP20210783T1 (hr)	2021-06-25	Derivati karboksamida
BR0110240A (pt)	2003-01-07	Composto, processo para a preparação de um composto, processo para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica
TW200932743A (en)	2009-08-01	Azole carboxamide compounds or salts thereof
AR065824A1 (es)	2009-07-01	Sulfonilbenzamidas sustituidas con heterociclos bloqueantes de los canales de sodio,formulaciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del dolor y particularmente del dolor cronico.
JP2013542247A (ja)	2013-11-21	Ｈｉｖ複製の阻害剤
AR047890A1 (es)	2006-03-01	Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3
ATE487715T1 (de)	2010-11-15	Triazolderivate als modulatoren von dopamin-d3- rezeptoren
CA2445333A1 (fr)	2002-11-07	Derives de quinoline et de quinazoline ayant un groupe azolyle
AR037736A1 (es)	2004-12-01	Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r)
AR065719A1 (es)	2009-06-24	Imidazo y triazolopirimidinas, un procedimiento para su preparacion y su uso en la elaboracion de un medicamento para el tratamiento de trastornos hematologicos.
KR20230026404A (ko)	2023-02-24	Nav1.8 억제제로서의 2-옥소-옥사졸리딘-5-카르복스아미드
HRP20110938T1 (hr)	2012-01-31	Spojevi koji sadrže gvanidin i koji se koriste kao agonisti muskarinskih receptora
AU2014234909A1 (en)	2015-08-13	Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors
AR111808A1 (es)	2019-08-21	Derivados de pirimidina como moduladores del receptor de pge2
HRP20230313T1 (hr)	2023-05-12	Modulatori receptora cxcr7 piperidina
AR109650A1 (es)	2019-01-09	Compuestos de heteroarilcarboxamida como inhibidores de ripk2